Management of Transient Ischemic Attack (TIA) and acute stroke;Management der Transienten Ischämischen Attacke (TIA) und des akuten hirnschlags

Praxis

Volumn 101, Issue 6, 2012, Pages 389-397

  Heldner, M R ^a   Arnold, M ^a   Gralla, J ^a   Fischer, Urs ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute stroke; Management; Secondary prevention; Transient ischemic attack

Indexed keywords

BLOOD CLOT LYSIS; DISABILITY; ENDOVASCULAR SURGERY; HUMAN; PROPHYLAXIS; SECONDARY PREVENTION; SHORT SURVEY; STROKE; STROKE UNIT; TRANSIENT ISCHEMIC ATTACK;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOPLASTY; CEREBRAL ANGIOGRAPHY; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALS, SPECIAL; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; RECURRENCE; STROKE; SWITZERLAND; THROMBOLYTIC THERAPY;

EID: 84858431686     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a000866     Document Type: Short Survey

References (60)

1. Warlow C, Van Gijn J, Dennis MS, et al.: Stroke: Practical Management (3rd ed.). Blackwell Pub: Oxford 2008.
2. Easton JD, Saver JL, Albers GW, et al.:Definition and evaluation of transient ischemic attack. A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke 2009; 40: 2276-2293.
3. Bots ML, van der Wilk EC, Koudstaal PJ, Hofmann A,Grobbee DE: Transient neurological attacks in the general population. Prevalence, risk factors and clinical relevance. Stroke 1997; 28: 768-773. (Pubitemid 27161461)
4. Rothwell PM, Giles MF, Flossmann E, et al.: A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischemic attack. Lancet 2005; 366: 29-36. (Pubitemid 40956527)
5. Lovett JK, Coull AJ, Rothwell PM: Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-573. (Pubitemid 38252797)
6. Johnston SC, Gress DR, Browner WS, Sidney S: Short-termprognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-2906.
7. Coull AJ, Lovett JK, Rothwell PM:On behalf of the Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack orminor stroke: implications for public education and organization of services. BMJ 2004; 328: 326.
8. Chandratheva A, Mehta Z, Geraghty OC, et al.: And on behalf of the Oxford Vascular Study. Population based study of risk and predictors of stroke in the first few hours after a TIA.Neurology 2009; 72: 1941-1947.
9. Rothwell PM, Giles MF, Chadrathewa A, et al.: Effect of urgent treatment of transient ischemic attack andminor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2008; 370: 1398-1400.
10. Chandratheva A, Geraghty OC, Rothwell OM: Poor performance of current prognostic scores for early risk of recurrence after minor stroke. Stroke 2011; 42: 632-637.
11. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL: AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999; 30: 2502-2511. (Pubitemid 29517756)
12. Dengler R, Diener HC, Schwartz A, et al.: EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 159-166.
13. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. NEJM 1995; 333: 1581-1587.
14. Hacke W, Kaste M, Bluhmki E, et al.: ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008; 359: 1317-1329.
15. Layton KF, White JB, Cloft HJ, Kallmes DF, Manno EM. Expanding the treatment window withmechanical thrombectomy in acute ischemic stroke. Neuroradiology 2006; 48: 402-404. (Pubitemid 43923161)
16. Furlan A, Higashida R, Wechsler L, et al.: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282: 2003-2011.
17. Mattle HP, Arnold M, Gerogiadis D, et al.: Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008; 39: 379-383. (Pubitemid 351619459)
18. Brott T, Bogousslavsky J: Treatment of acute ischemic stroke. NEJM 2000; 388: 710-722.
19. Hart RG, Sherman DG, Easton JD, Cairns JA: Prevention of stroke in patients with nonvalvular atrial fibrillation.Neurology 1998; 51: 674-681. (Pubitemid 28449242)
20. Segal JB, McNamara RL, Miller MR, et al.: Prevention of thromboembolismin atrial fibrillation. Ameta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen InternMed 2000; 15: 56-67. (Pubitemid 30060940)
21. Lamy A, Tong W, Gao P, et al.:The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol 2011;10 [Epub ahead of print].
22. Veltkamp R, Hacke W: New oral anticoagulants in atrial fibrillation. Nervenarzt 2011; 82: 182-184.
23. Georgiadis D, Arnold M, von Buedingen HC, et al.: Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. Neurology 2009; 72: 1810-1815.
24. Bonati LH, Fraedrich G: Carotid Stenting Trialists' Collaboration: Age modifies the relative risk of stenting versus endarterectomy for symptomatic carotid stenosis - a pooled analysis of EVA-35, SPACE and ICSS. Eur J Vasc Endovasc Surg 2011; 41: 153-158.
25. Carotid Stenting Trialists' Collaboration: Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a pre-planned meta-analysis of individual patient data. Lancet 2010; 376: 1062-1073.
26. International Carotid Stenting Study investigators. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomized controlled trial. Lancet 2010; 375: 985-997.
27. CREST Investigators: Stenting versus endarterectomy for treatment of carotid-artery stenosis.NEJM2010; 363: 11-23.
28. Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group: 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomized trial. Lancet 2010; 376: 1074-1084.
29. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al.: Comparison of Warfarin and Aspirin for symptomatic intracranial arterial stenosis. NEJM 2005; 352: 1305-1316.
30. Kasner SE, Chimowitz MI, Lynn MJ, et al.: Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113: 555-563.
31. Kurre W, Berkefeld J, Brassel F, et al.:The INTRASTENT Study Group. In-hospital complication rates after stent treatment of 388 symptomatic intracranial stenoses - results from the INTRASTENT Multicentric Registry. Stroke 2010; 41: 494-498.
32. Weber R, Kraywinkel K, Diener HC, Weimar C: German Stroke Study Collaboration. Symptomatic intracranial atherosclerotic stenoses: prevalence and prognosis in patients with acute cerebral ischemia. Cerebrovasc Dis 2010; 30: 188-193.
33. CLAIR study investigators: Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomized, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489-497.
34. Chimonitz MI, Lynn MS, Derdeyn CP, et al.: Stenting versus aggressive medical therapy for intracranial arterial Stenosis. NEJM 2011, 365: 993-1003.
35. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A: Patent foramen ovale and cryptogenic stroke in older patients. NEJM 2007; 357: 2262-2268. (Pubitemid 350190756)
36. Mas JL, Arquizan C, Lamy C, et al.: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.NEJM2001; 345: 1740-1746.
37. Messe S, Silverman I, Kizer J, et al.: Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 62: 1042-1050. (Pubitemid 38456495)
38. Slottow TL, Steinberg DH, Waksman R: Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation 2007; 116: 677-682. (Pubitemid 47356353)
39. Khairy P,O'Donnell CP, Landzberg MJ: Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003; 139: 753-760. (Pubitemid 38129075)
40. Lewington S, Whitlock G, Clarke R, et al.: Blood cholesterol and vascularmortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-1839.
41. Progress Collaborative Group: Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041.
42. Rashid P, Leonardi-Bee J, Bath P: Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741-2749.
43. Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884. (Pubitemid 37413724)
44. Müller-Wieland D, Nietschmann S: Cardiovascular risk in type 2 diabetes. ACCORD study (Action of Control Cardiovascular Risk in Diabetes). Internist 2011; 52: 601-604.
45. Schrader J, Lüders S, Kulschewski A, et al.:The ACCESS Study: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703. (Pubitemid 36842630)
46. Schrader J, Lüders S, Kulschewski A, et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
47. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
48. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor: ramipril, on cardiovascular events in high-risk patients. NEJM 2000; 342: 145-153.
49. Webb AJ, Fischer U, Metha Z, Rothwell PM: Effect of anti-hypertensive- drug class on interindividual variation in blood pressure and risk of stroke: a systemic review and meta-analysis. Lancet 2010; 375: 906-915.
50. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412. (Pubitemid 30609442)
51. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20'536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
52. Amarenco P, Goldstein LB, Szarek M, et al.: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38: 3198-3204. (Pubitemid 350175737)
53. Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298: 789-794. (Pubitemid 19084523)
54. Bejot Y,Giroud M: Epidemiological implications of primary and secondary stroke prevention. Handb Clin Neurol 2009; 92: 389-405.
55. Iso H, Date C, Yamato A, et al.: Smoking cessation and mortality from cardiovascular disease among Japanesemen and women: the JACC Study. AmJ Epidemiol 2005; 161: 170-179. (Pubitemid 40096792)
56. Gonzales D, Rennard SI, Nides M, et al.: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Ass 2006; 296: 47-55.
57. Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007: CD 000031.
58. Hu FB, Manson JE: Exercise intensity and risk of chronic disease. JAMA 2000; 284: 1784-1785.
59. He FJ, MacGregor GA: Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011; 378: 380-382.
60. He FJ, Nowson CA, MacGregor GA: Fruit and vegetable consumption and stroke:meta-analysis of cohort studies. Lancet 2006; 367: 320-326. (Pubitemid 43151465)